Patents Assigned to Ascentage Pharma (Suzhou) Co., Ltd.
-
Patent number: 11987575Abstract: The present disclosure provides compounds represented by Formula I, or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.Type: GrantFiled: July 29, 2020Date of Patent: May 21, 2024Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP, LIMITEDInventors: Yunlong Zhou, Guozhi Tang, Chao Li, Fang Liu, Yu Jing, Renlin Wang
-
Patent number: 11872237Abstract: The present invention relates to a pharmaceutical composition comprising a sulfonamide as an inhibitor of Bcl-2/Bcl-xL, especially compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoromethyl sulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester or a pharmaceutically acceptable salt thereof and suitable excipients, preferably a pharmaceutical composition in the form of a lyophilized powder. The invention also relates to a method for preparing the pharmaceutical composition.Type: GrantFiled: December 12, 2019Date of Patent: January 16, 2024Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Ming Guo, Yanqiong Lin, Zhenzhong Shao, Pengfei Cao
-
Patent number: 11850239Abstract: Provided herein is a method of treating, preventing, or alleviating one or more symptoms of a disorder, disease, or condition mediated by an MDM2 with an MDM2 inhibitor, e.g., a compound of Formula (I), and a platinum compound. Also provided herein is a method of inhibiting the growth of a cell with an MDM2 inhibitor and a platinum compound.Type: GrantFiled: December 18, 2020Date of Patent: December 26, 2023Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Yifan Zhai, Dajun Yang
-
Patent number: 11787814Abstract: Disclosed is a method for preparing 2-indolinospirone compound and intermediate thereof, specifically disclosed is a method for preparing a compound of formula 5. The method is relatively simple and has high stereoselectivity and yield.Type: GrantFiled: July 10, 2020Date of Patent: October 17, 2023Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Ming Guo, Jianfeng Wen, Jianpeng Feng, Tianzhu Wu, Huirong Lu
-
Patent number: 11691989Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.Type: GrantFiled: November 20, 2019Date of Patent: July 4, 2023Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Hao Chen, Wenming Chen, Chao Li, Dongbo Li, Yu Jing, Guozhi Tang, Yunlong Zhou, Shaomeng Wang, Chao-Yie Yang
-
Publication number: 20230159524Abstract: Disclosed is a method for synthesizing N-(phenylsulfonyl)benzamide compound and intermediate thereof. The method comprises a method for synthesizing a compound 1, comprising conducting a Buchwald-Hartwig coupling reaction as shown below with compound A and compound B in a solvent and in the presence of a base and a palladium catalyst to obtain the compound 1; wherein R is C1-C8 alkyl. The present disclosure synthesizes three intermediate compounds required by the target compound and their preparation methods for the first time. Using the method disclosed in the present disclosure to synthesize the target compound 3 has the advantages of high yield, good purity, easy-to-obtain reaction raw materials, suitable for industrial production.Type: ApplicationFiled: July 1, 2021Publication date: May 25, 2023Applicants: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Jianfeng WEN, Jianyong CHEN, Yunlong ZHOU, Jianpeng FENG, Ming GUO, Tianzhu WU, Minmin CAI, Yu JING, Lingling JIAO
-
Publication number: 20230159518Abstract: The present invention provides crystalline forms or amorphous forms of N-(phenylsulfonyl) benzoamide compound or its salts or solvates used as a Bcl-2 inhibitor, and the preparation method and the application thereof.Type: ApplicationFiled: March 5, 2021Publication date: May 25, 2023Applicants: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Jianfeng WEN, Jianpeng FENG, Tianzhu WU, Weidong LI, Yanqiong LIN
-
Publication number: 20230064976Abstract: Amorphous form or crystalline form of a 2-indolinolinololylspironone compound or its salt and solvate used as an MDM2 inhibitor, a preparation method and an application thereof. The amorphous form or crystalline form of the invention has good stability and is of great value for drug development, preparation development and production.Type: ApplicationFiled: January 22, 2021Publication date: March 2, 2023Applicants: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Jianfeng WEN, Jianpeng FENG, Tianzhu WU, Weidong LI, Yanqiong LIN, Zongbin LI
-
Patent number: 11554127Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor, an anti-CD20 antibody and/or bendamustine or a combination product comprising a Bcl-2 inhibitor and CHOP, the combination product provides a use of the combination product for prevention and/or treatment of a disease (e.g., cancer, rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis).Type: GrantFiled: July 22, 2019Date of Patent: January 17, 2023Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Dajun Yang, Yifan Zhai, Guangfeng Wang
-
Patent number: 11498928Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.Type: GrantFiled: January 17, 2020Date of Patent: November 15, 2022Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Jianyong Chen, Yunlong Zhou, Guozhi Tang, Chengzhe Wu, Leilei Zhao, Lingling Jiao, Binghua Sheng, Shaomeng Wang, Chao-Yie Yang, Hao Chen, Wenliang Hu, Yu Jing
-
Patent number: 11491168Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.Type: GrantFiled: April 27, 2020Date of Patent: November 8, 2022Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Yifan Zhai, Dajun Yang
-
Patent number: 11491167Abstract: The present invention relates to a combination product comprising a Bcl-2 inhibitor and a chemotherapeutic agent, and the combination product provides a use in the prevention and/or treatment of diseases (e.g., cancer).Type: GrantFiled: July 22, 2019Date of Patent: November 8, 2022Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Dajun Yang, Yifan Zhai, Guangfeng Wang
-
Patent number: 11478477Abstract: The present invention pertains to the biomedical field, and particularly relates to a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and a therapeutically effective amount of an EGFR inhibitor. The invention also relates to a pharmaceutical composition or kit comprising one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and an EGFR inhibitor.Type: GrantFiled: July 22, 2019Date of Patent: October 25, 2022Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Dajun Yang, Yifan Zhai, Douglas Dong Fang, Guangfeng Wang
-
Patent number: 11478470Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bc1-2/Bc1-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).Type: GrantFiled: July 30, 2019Date of Patent: October 25, 2022Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Dajun Yang, Yifan Zhai, Douglas Dong Fang, Guangfeng Wang, Guoqin Zhai
-
Patent number: 11478469Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor and an MDM-2 inhibitor, the combination product providing a use in the prevention and/or treatment of diseases (e.g., cancer).Type: GrantFiled: July 22, 2019Date of Patent: October 25, 2022Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.Inventors: Dajun Yang, Yifan Zhai, Qiuqiong Tang, Douglas Dong Fang
-
Patent number: 11452716Abstract: Disclosed is a pharmaceutical composition comprising (i) a compound of formula (I) or a pharmaceutically acceptable salt thereof; (ii) a CDK inhibitor or a pharmaceutically acceptable salt thereof, for the prevention and/or treatment of a disease mediated by MDM2 and/or CDK activity.Type: GrantFiled: June 8, 2020Date of Patent: September 27, 2022Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Dajun Yang, Yifan Zhai, Douglas Dong Fang, Qiuqiong Tang
-
Patent number: 11414400Abstract: The present invention relates to a method for preparing sulfonamides which are inhibitors of Bcl-2/Bcl-xL, comprising the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoro methylsulfonyl-anilino)-4-phenylthio-butyl)-4-hydroxyl-piperidine, and the present invention also relates to intermediates for the preparation of the sulfonamides, a new final product and its therapeutic use, and pharmaceutical use.Type: GrantFiled: January 3, 2020Date of Patent: August 16, 2022Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Ming Guo, Jianfeng Wen, Tianzhu Wu, Huirong Lu, Feng Xu
-
Patent number: 11395815Abstract: The present invention relates to a compound for treating or preventing osteoarthritis. The compound relieves the joint pain, inhibits and attenuates the development of post-traumatic osteoarthritis in mouse model. The present invention also provides a pharmaceutical composition comprising the compound for treating or preventing osteoarthritis. The present invention further provides a method for treating or preventing osteoarthritis by administrating to the patient in need thereof with the pharmaceutical composition.Type: GrantFiled: March 24, 2020Date of Patent: July 26, 2022Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITEDInventors: Dajun Yang, Yifan Zhai, Douglas Dong Fang, Saijie Zhu
-
Patent number: 11370807Abstract: The present invention relates to a process for preparing a sulfonamide compound which is an inhibitor of Bcl-2/Bcl-xL, including the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazine-1-yl)-phenylaminosulfonyl)-2-trifluoromethanesulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester. The present invention also relates to an intermediate for preparing the sulfonamide compound and a preparation process thereof.Type: GrantFiled: January 3, 2020Date of Patent: June 28, 2022Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp LimitedInventors: Ming Guo, Jianfeng Wen, Huirong Lu, Jianpeng Feng, Jing Zhang, Ming Jin, Qianlei Cao